## Background: A new, total-immersion three-dimensional histoculture (tih) method was developed to evaluate growth of tissue containing a mixture of benign prostate hyperplasia (bph) and prostate cancer in vitro. ## Methods: Efficacy of inhibitors, such as genistein, was determined by measuring 3
Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture
โ Scribed by Geller, Jack; Sionit, Lida; Partido, Christine; Li, Lingna; Tan, Xiuying; Youngkin, Tyler; Nachtsheim, Daniel; Hoffman, Robert M.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 179 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
There is strong epidemiological evidence that prostate disease is significantly less prevalent in the orient, where the intake of soy products is very high, than in the united states. we therefore undertook a study of the effects of genistein, a major component of soy, on growth of human-patient benign prostatic hypertrophy (bph) and prostate cancer tissue in three-dimensional collagen gel-supported histoculture.
Methods:
Surgical specimens of human bph and cancer were histocultured for 5 days to study the effects of genistein on growth, as measured by inhibition of 3h-thymidine incorporation per microgram protein on day 5.
Results:
Genistein in doses of 1.25-10 micrograms/ml decreased the growth of bph tissue in histoculture in a dose-dependent manner, with little additional effect at higher doses. prostate cancer tissue in histoculture was similarly inhibited by these doses of genistein.
Conclusions:
Genistein decreases the growth of both bph and prostate cancer tissue in histoculture. the data suggest that genistein has potential as a therapeutic agent for bph and prostate cancer.
๐ SIMILAR VOLUMES
## BACKGROUND. In order to determine androgen sensitivities of prostate cancer and benign prostatic hypertrophy (BPH) tissues from the same patient in vitro, we used a histoculture technique to measure androgen-independent and androgen-dependent growth and compared them in paired specimens of BPH
## BACKGROUND. In prostate cancer, we and others have observed distinct phenotypic responses to interleukin-6 (IL-6), which acts either as a paracrine growth inhibitor in the LNCaP cell line or as an autocrine growth stimulator in PC-3, DU145, and TSU cell lines. To understand the underlying mechan
## Background: Receptors for luteinizing hormone-releasing hormone (lh-rh) found in prostate cancers might be used for targeting of chemotherapeutic agents. doxorubicin derivative 2-pyrrolinodoxorubicin (an-201) can be linked to carrier analog [d-lys6]lh-rh to form the targeted cytotoxic analog of
BACKGROUND. Epidemiological reports suggest that Asians consuming a diet high in soy have a low incidence of prostate cancer. In animal models, soy and genistein have been demonstrated to suppress the development of prostate cancer. In this study, we investigate the mechanism of action, bioavailabil